{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:45Z","timestamp":1787315265233,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jpba.2021.114287","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:18:31Z","timestamp":1627449511000},"page":"114287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Simultaneous monitoring of multiple attributes of pyrrolobenzodiazepine antibody-drug conjugates by size exclusion chromatography \u2013 high resolution mass spectrometry"],"prefix":"10.1016","volume":"205","author":[{"given":"Florian","family":"F\u00fcssl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor S.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-1522","authenticated-orcid":false,"given":"K. Phin","family":"Chooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakumar","family":"Vijayakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyoung-Dong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"von Bulow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-2592","authenticated-orcid":false,"given":"Jonathan","family":"Bones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpba.2021.114287_bib0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"16","key":"10.1016\/j.jpba.2021.114287_bib0010","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.jpba.2021.114287_bib0015","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"30","key":"10.1016\/j.jpba.2021.114287_bib0020","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.tetlet.2015.05.116","article-title":"Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs","volume":"56","author":"Kolakowski","year":"2015","journal-title":"Tetrahedron Lett."},{"issue":"7","key":"10.1016\/j.jpba.2021.114287_bib0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.jpba.2021.114287_bib0030","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2021.114287_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","article-title":"The impact of glycosylation on the biological function and structure of human immunoglobulins","volume":"25","author":"Arnold","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.jpba.2021.114287_bib0040","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"18","key":"10.1016\/j.jpba.2021.114287_bib0045","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1021\/acs.jpclett.5b01588","article-title":"Glycosylation may reduce protein thermodynamic stability by inducing a conformational distortion","volume":"6","author":"Gavrilov","year":"2015","journal-title":"J. Phys. Chem. Lett."},{"issue":"1","key":"10.1016\/j.jpba.2021.114287_bib0050","doi-asserted-by":"crossref","first-page":"12659","DOI":"10.1038\/s41598-017-12830-5","article-title":"Effects of N-Glycan composition on structure and dynamics of IgG1 fc and their implications for antibody engineering","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jpba.2021.114287_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.jpba.2021.114287_bib0060","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/ac203346c","article-title":"Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues","volume":"84","author":"Valliere-Douglass","year":"2012","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jpba.2021.114287_bib0065","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1021\/ac302959p","article-title":"Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates","volume":"85","author":"Chen","year":"2013","journal-title":"Anal. Chem."},{"issue":"21","key":"10.1016\/j.jpba.2021.114287_bib0070","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1021\/ac502593n","article-title":"Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment","volume":"86","author":"Debaene","year":"2014","journal-title":"Anal. Chem."},{"issue":"8","key":"10.1016\/j.jpba.2021.114287_bib0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/pro.2666","article-title":"Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate","volume":"24","author":"Marcoux","year":"2015","journal-title":"Protein Sci."},{"issue":"5","key":"10.1016\/j.jpba.2021.114287_bib0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/19420862.2017.1316914","article-title":"Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates","volume":"9","author":"Botzanowski","year":"2017","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.jpba.2021.114287_bib0085","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1080\/19420862.2015.1083665","article-title":"A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography","volume":"7","author":"Birdsall","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2021.114287_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpba.2014.04.011","article-title":"Theory and practice of size exclusion chromatography for the analysis of protein aggregates","volume":"101","author":"Fekete","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114287_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchromb.2017.09.027","article-title":"Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation","volume":"1065-1066","author":"Goyon","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.jpba.2021.114287_bib0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1122150","article-title":"Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry","volume":"8","author":"Haberger","year":"2016","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.jpba.2021.114287_bib0105","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s11095-010-0224-5","article-title":"Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography","volume":"27","author":"Kukrer","year":"2010","journal-title":"Pharm. Res."},{"issue":"13","key":"10.1016\/j.jpba.2021.114287_bib0110","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/rcm.1987","article-title":"Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry","volume":"19","author":"Lazar","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"3","key":"10.1016\/j.jpba.2021.114287_bib0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/19420862.2018.1433973","article-title":"Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry","volume":"10","author":"Friese","year":"2018","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.jpba.2021.114287_bib0120","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1021\/ac403860c","article-title":"Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry","volume":"86","author":"Hengel","year":"2014","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2021.114287_bib0125","doi-asserted-by":"crossref","first-page":"1682895","DOI":"10.1080\/19420862.2019.1682895","article-title":"Native size-exclusion chromatography-mass spectrometry: suitability for antibody-drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels","volume":"12","author":"Jones","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2021.114287_bib0130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejmech.2019.06.044","article-title":"Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual beta-glucuronide and dipeptide triggers","volume":"179","author":"Gregson","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.jpba.2021.114287_bib0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1568026619666190401112517","article-title":"Potentiation of PBD dimers by lipophilicity manipulation","volume":"19","author":"Cailleau","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jpba.2021.114287_bib0140","series-title":"Pyrrolobenzodiazepines and Conjugates Thereof","author":"Howard","year":"2019"},{"issue":"5","key":"10.1016\/j.jpba.2021.114287_bib0145","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","article-title":"Efficient preparation of site-specific antibody-drug conjugates using cysteine insertion","volume":"14","author":"Dimasi","year":"2017","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jpba.2021.114287_bib0150","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"20","key":"10.1016\/j.jpba.2021.114287_bib0155","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jpba.2021.114287_bib0160","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/jps.23018","article-title":"Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release","volume":"101","author":"Jiskoot","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.jpba.2021.114287_bib0165","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1134\/S0006297913070031","article-title":"Mass spectrometry of glycans","volume":"78","author":"Han","year":"2013","journal-title":"Biochem. Mosc."},{"issue":"22","key":"10.1016\/j.jpba.2021.114287_bib0170","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1021\/ja0705994","article-title":"Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage","volume":"129","author":"Cohen","year":"2007","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.jpba.2021.114287_bib0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchromb.2004.12.033","article-title":"Non-enzymatic hinge region fragmentation of antibodies in solution","volume":"818","author":"Cordoba","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"8","key":"10.1016\/j.jpba.2021.114287_bib0180","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s11095-008-9606-3","article-title":"Fragmentation of a recombinant monoclonal antibody at various pH","volume":"25","author":"Gaza-Bulseco","year":"2008","journal-title":"Pharm. Res."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:06Z","timestamp":1760001246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521003988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"alternative-id":["S0731708521003988"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114287","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous monitoring of multiple attributes of pyrrolobenzodiazepine antibody-drug conjugates by size exclusion chromatography \u2013 high resolution mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114287"}}